v3.26.3
Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)
3 Months Ended 9 Months Ended 115 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 29, 2026
Jan. 01, 2026
Summary of Significant Accounting Policies [Line Items]              
Loss recognized from uninsured balances         $ 0    
Accounting Standards Update [Extensible Enumeration]     us-gaap:AccountingStandardsUpdate202507Member        
Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false] true   true   true    
Change in Accounting Principle, Accounting Standards Update, Adoption Date             Jan. 01, 2026
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] false   false   false    
Mantle Therapeutics Inc.              
Summary of Significant Accounting Policies [Line Items]              
Potential future cash-based payments           $ 30,600,000  
Mantle Therapeutics Inc. | Cash              
Summary of Significant Accounting Policies [Line Items]              
Potential future cash-based payments           10,000,000  
Mantle Therapeutics Inc. | Cash | Development and Regulatory-based Milestones              
Summary of Significant Accounting Policies [Line Items]              
Potential future cash-based payments $ 28,600,000   $ 28,600,000   $ 28,600,000 $ 28,600,000  
Exercise of Outstanding Stock Options              
Summary of Significant Accounting Policies [Line Items]              
Antidilutive securities excluded from Computation of diluted net loss per common share 21,478,889 19,295,632 21,478,889 19,295,632